
Annovis Bio (ANVS) Stock Forecast & Price Target
Annovis Bio (ANVS) Analyst Ratings
Bulls say
Annovis Bio is viewed positively because its flagship buntanetap has already shown positive Phase 2b cognitive data in mild Alzheimer's disease, while its pivotal Phase 3 trial is fully enrolled with 850 patients and top-line 6M data still expected in 1Q27. The company’s broader pipeline in Parkinson’s disease, Lewy body dementia, traumatic brain injury, and stroke adds multiple shots on goal, but the investment case is most dependent on a clinically meaningful 6M ADAS-Cog13 benefit and the potential for NDA or sNDA filings. Fundamentally, the setup is compelling because the unmet need in neurodegeneration is large, yet the balance sheet is tight with $2.8M cash at 3Q26-end, ~$12M quarterly burn, and likely future dilution.
Bears say
Annovis Bio is under pressure because its cash balance fell to $2.8M at 3Q26-end from $18.7M at 2Q26-end, leaving continued going-concern doubt even after a November 6 offering that raised about $19.6M net and added substantial dilution. The stock looks driven more by financing and listing risk than by fundamentals, with shares down 73% YTD to $0.93 and a market cap of about $57M, while the company also faces a continued-listing notice tied to market cap and stockholders’ equity below $50M. With management funding operations only through the March 2027 topline readout, the investment case remains highly dependent on a positive Ph3 result despite meaningful clinical, regulatory, and commercialization risk across buntanetap, ANVS405, and ANVS301.
This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.
Annovis Bio (ANVS) Analyst Forecast & Price Prediction
Start investing in Annovis Bio (ANVS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Annovis Bio (ANVS) Forecast
Annovis Bio (ANVS) Analyst Forecast & Price Prediction
Start investing in Annovis Bio (ANVS)
Order type
Buy in
Order amount
Est. shares
0 shares